HeartBeam (Nasdaq:BEAT) announced today that it received FDA 510(k) clearance for its 12-lead electrocardiogram (ECG) ...
HeartBeam's 1st synthesized 12-lead ECG cleared by FDA, enabling cable-free at-home arrhythmia assessment with launch set for 2026.
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, ...
TipRanks on MSN
HeartBeam (NASDAQ: BEAT) secures FDA 510(k) clearance for 12-lead ECG synthesis software following successful appeal
Austin, Texas, United States, December 10th, 2025, FinanceWire HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming ...
Austin, Texas, United States, December 18th, 2025, FinanceWire HeartBeam (NASDAQ: BEAT), a medical-technology company ...
AliveCor has spent years battling with Apple over the market for consumer heart monitoring technology. Now it’s hoping to make its imprint on professional health care with its new device, which ...
Beginning in February, Kern County will become the first in the state to equip all EMS providers with handheld, AI-enabled 12 ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced ...
Unlike any single-lead or 6-lead consumer device, HeartBeam’s patented cable-free technology captures the heart’s electrical signals in three non-coplanar dimensions and synthesizes them into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback